ARK Investment Management LLC Decreases Stake in Natera, Inc. $NTRA

ARK Investment Management LLC decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 4.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 892,593 shares of the medical research company’s stock after selling 43,799 shares during the period. ARK Investment Management LLC owned approximately 0.65% of Natera worth $143,681,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Sound Income Strategies LLC raised its stake in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC purchased a new position in Natera in the third quarter valued at about $46,000. Hilltop National Bank lifted its stake in shares of Natera by 59.8% during the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after purchasing an additional 116 shares in the last quarter. N.E.W. Advisory Services LLC boosted its position in shares of Natera by 256.8% in the second quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after buying an additional 226 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of Natera by 23.1% in the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after buying an additional 81 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Natera Stock Down 1.9%

Shares of Natera stock opened at $203.03 on Thursday. The business has a 50-day moving average price of $224.59 and a 200 day moving average price of $204.76. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm has a market cap of $28.78 billion, a P/E ratio of -132.70 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same quarter in the previous year, the firm earned ($0.41) earnings per share. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of analyst reports. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Wells Fargo & Company boosted their target price on shares of Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. TD Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday, January 7th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, UBS Group raised their target price on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $253.47.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $199.85, for a total value of $599,550.00. Following the completion of the transaction, the insider owned 150,023 shares in the company, valued at approximately $29,982,096.55. This represents a 1.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 3,950 shares of Natera stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $200.02, for a total value of $790,079.00. Following the sale, the chief executive officer directly owned 156,607 shares in the company, valued at approximately $31,324,532.14. This trade represents a 2.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 367,669 shares of company stock valued at $85,584,453. 5.63% of the stock is owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.